![]() | Up a level |
Hillmen, Peter, Rawstron, Andy C, Brock, Kristian, Muñoz-Vicente, Samuel, Yates, Francesca J, Bishop, Rebecca, Boucher, Rebecca, MacDonald, Donald, Fegan, Christopher, McCaig, Alison et al (show 9 more authors)
(2019)
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Journal of Clinical Oncology, 37 (30).
pp. 2722-2730.
Copland, Mhairi, Slade, Daniel, McIlroy, Graham, Horne, Gillian, Byrne, Jenny L, Rothwell, Kate, Brock, Kristian, De Lavallade, Hugues, Craddock, Charles, Clark, Richard E ORCID: 0000-0002-1261-3299 et al (show 5 more authors)
(2022)
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
LANCET HAEMATOLOGY, 9 (2).
E121-E132.
Pratt, Guy, Yap, Christina, Oldreive, Ceri, Slade, Daniel, Bishop, Rebecca, Griffiths, Mike, Dyer, Martin JS, Fegan, Chris, Oscier, David, Pettitt, Andrew et al (show 9 more authors)
(2018)
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
BRITISH JOURNAL OF HAEMATOLOGY, 182 (3).
pp. 429-433.